title: Mesenchymal stem cells in combination with erythropoietin repair hyperoxia-induced alveoli dysplasia injury in neonatal mice via inhibition of TGF-β1 signaling.
abstract: The aim of the present study is to investigate the protection effects of bone marrow mesenchymal stem cells (MSCs) in combination with EPO against hyperoxia-induced bronchopulmonary dysplasia (BPD) injury in neonatal mice. BPD model was prepared by continuous high oxygen exposure, 1×106 bone marrow MSCs and 5000U/kg recombinant human erythropoietin (EPO) were injected respectively. Results showed that administration of MSCs, EPO especially MSCs+EPO significant attenuated hyperoxia-induced lung damage with a decrease of fibrosis, radical alveolar counts and inhibition of the occurrence of epithelial-mesenchymal transition (EMT). Furthermore, MSCs+EPO co-treatment more significantly suppressed the levels of transforming growth factor-β1(TGF-β1) than MSCs or EPO alone. Collectively, these results suggested that MSCs, EPO in particular MSCs+EPO co-treatment could promote lung repair in hyperoxia-induced alveoli dysplasia injury via inhibition of TGF-β1 signaling pathway to further suppress EMT process and may be a promising therapeutic strategy.
authors.affiliation: Central Research Laboratory, The Second Hospital of Shandong University, Jinan, China.
authors.forename: Yun
authors.initials: Y
authors.lastname: Luan
authors.affiliation: Department of Pediatrics, The Second Hospital of Shandong University, Jinan, China.
authors.forename: Luan
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Central Research Laboratory, The Second Hospital of Shandong University, Jinan, China.
authors.forename: Sun
authors.initials: S
authors.lastname: Chao
authors.affiliation: Department of Hematology, The Second Hospital of Shandong University, Jinan, China.
authors.forename: Xiaoli
authors.initials: X
authors.lastname: Liu
authors.affiliation: Central Research Laboratory, The Second Hospital of Shandong University, Jinan, China.
authors.forename: Kaili
authors.initials: K
authors.lastname: Li
authors.affiliation: Department of Pediatrics, The Second Hospital of Shandong University, Jinan, China.
authors.forename: Yibiao
authors.initials: Y
authors.lastname: Wang
authors.affiliation: Department of Pediatrics, The Second Hospital of Shandong University, Jinan, China.
authors.forename: Zhaohua
authors.initials: Z
authors.lastname: Zhang
mesh_terms: D000818:Animals; D001997:Bronchopulmonary Dysplasia / Q000209:etiology / Q000628:therapy*; D002478:Cells, Cultured; D003131:Combined Modality Therapy / Q000379:methods; D004195:Disease Models, Animal; D058750:Epithelial-Mesenchymal Transition / Q000187:drug effects; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D005355:Fibrosis / Q000188:drug therapy; D006801:Humans; D018496:Hyperoxia / Q000150:complications; D045164:Mesenchymal Stem Cell Transplantation; D051379:Mice; D008810:Mice, Inbred C57BL; D011650:Pulmonary Alveoli / Q000187:drug effects / Q000473:pathology*; D011994:Recombinant Proteins / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects; D053773:Transforming Growth Factor beta1 / Q000378:metabolism*
chemical_list: C554270:EPO protein, human; D011994:Recombinant Proteins; D053773:Transforming Growth Factor beta1; D004921:Erythropoietin
keywords: BPD; EPO; ETM; MSCs; TGF-β1